Articles related to BARIATRIC SURGERY

Phase 3 TRIUMPH-1 trial results for retatrutide, a triple hormone agonist targeting GIP, GLP-1, and glucagon receptors, showed up to 28.3% mean weight loss at 80 weeks and 30.3% in patients with BMI ≥35 at 104 weeks — the largest weight reduction reported in a medication trial to date, per Lilly’s press release.

Two Lilly-sponsored placebo-controlled trials found that adults who transitioned from high-dose injectable GLP-1 therapy to either oral tirzepatide (Foundayo) or a reduced 5 mg tirzepatide maintenance dose preserved most of their prior weight loss over one year, compared to substantial regain in placebo arms.

Bariatric surgery volumes peaked in 2022 and have fallen since, with sleeve gastrectomy losing ground and Roux-en-Y conversions climbing as GLP-1 prescriptions expand.

Women who are overweight have an increased risk of developing breast cancer. It is unknown whether prior obesity still carries a higher baseline risk of breast cancer in women who have shed a significant amount of weight as compared to peers without obesity. Researchers assembled a retrospective matched cohort study of 69,260 women who were followed up for 5 years after bariatric surgery or the index date (1/1/2010 – 12/31/2016) to see whether there is a residual risk of breast cancer among patients who undergo bariatric surgery due to prior obesity. According to the findings, bariatric surgery was linked to a lower risk of breast cancer in women with prior obesity that was equivalent to a woman with a BMI under 25, as well as a lower risk when compared to all groups with a BMI of 25 or higher.